vcmmae

VCMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity.

VcMMAE-Deruxtecan is a toxic molecular conjugate (Drug-Linker Conjugates for ADC) composed of a linker and cytotoxic agents MMAE (microtubule inhibitor) and Exatecan (DNA topoisomerase I inhibitor). This compound is employed in the synthesis of ADCs.

VcMMAE-Eribulin is a (Drug-Linker Conjugates for ADC) composed of the linker and cytotoxic molecules MMAE and Eribulin. This conjugate is used in the synthesis of ADCs.

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB). Glembatumumab vedotin has potent anticancer effects and can be used in the study of triple negative breast cancer (TNBC).

MRG003 is an antibody-drug conjugate (ADC) composed of the humanized anti-EGFR IgG1 monoclonal antibody, Becotatug, coupled with MMAE. These components are linked through a valine-citrulline (valine-citrulline) connector, forming the Drug-Linker conjugate VcMMAE within the ADC.